BioSpace News Archive

AstraZeneca reported successful results from its Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end stage kidney disease (ESKD).

Less than one week after forging a vaccine manufacturing agreement with Novavax, FUJIFILM Diosynth Biotechnologies announced its College Station, Texas facility was selected by the federal government to support COVID-19 vaccine candidate manufacturing.

Although COVID-19 primarily presents itself as a respiratory disease, a number of associations have been discovered between the microbiomes and a number of diseases.

The U.S. House of Representatives approved a $3.2 billion budget proposal for the U.S. Food and Drug Administration (FDA) that will boost the agency’s abilities to approve new medicines and medical devices, as well as protect the nation’s food supplies.

A study published in the journal Cell Stem Cell today revealed how aging can cause lung regeneration to go awry, which can potentially lead to lung cancer and other diseases.

The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).

JLL published its JLL 2020 U.S. Life Sciences Outlook, which ranks and tracks the progress of life sciences markets, particularly in how they relate to real estate development.

“We are pleased with and excited by this financing, which supports our continued mission to develop best-in-class therapies that deliver long-term value to human health,” said Marcio Souza, president and chief executive officer of Praxis.

CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity in support of selecting a recommended Phase 2 dose

Micron Medical, a privately-held medical device company engaged in the development, manufacture and pre-commercialization of innovative wireless, minimally invasive, electroceutical solutions for urological conditions, today announced the appointment of Nick Ansari as Senior Vice President of Sales. Mr. Ansari has an impressive track record of success with more than 25 years of experience in field sales and commercialization in the medical de